Spago Nanomedical AB (SE:SPAGO)
:SPAGO
Want to see SE:SPAGO full AI Analyst Report?
Top Page
Spago Nanomedical AB
(SPAGO)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr0.11
▲(12.00% Upside)
Action:Reiterated
Date:05/28/26
The score is primarily weighed down by weak financial performance (ongoing losses and cash burn), with only partial support from a debt-free balance sheet. Technical indicators are mixed but generally soft with a near-oversold signal, while valuation is limited by the negative P/E and lack of dividend yield.
Positive Factors
Debt-free balance sheet
A zero-debt balance sheet materially reduces refinancing and interest-rate risk for a pre-revenue biotech. This structural strength preserves flexibility to fund clinical programs through equity, partnerships or grants, supporting sustained R&D progress without fixed debt servicing burdens.
Negative Factors
Persistent cash burn
Sustained negative operating cash flow shows the company remains cash-consuming and dependent on external capital. Over months this structural cash burn limits runway, increases dilution risk from new financings, and constrains the firm's ability to advance multiple clinical programs concurrently.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt balance sheet materially reduces refinancing and interest-rate risk for a pre-revenue biotech. This structural strength preserves flexibility to fund clinical programs through equity, partnerships or grants, supporting sustained R&D progress without fixed debt servicing burdens.
Read all positive factors
Spago Nanomedical AB (SPAGO) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr95.01M
Dividend YieldN/A
Average Volume (3M)1.01M
Price to Earnings (P/E)―
Beta (1Y)1.07
Revenue Growth-93.63%
EPS Growth29.24%
CountrySE
Employees13
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.04
Shares Outstanding808,588,800
10 Day Avg. Volume1,158,815
30 Day Avg. Volume1,005,829
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.42
Price to Sales (P/S)99.92
P/FCF Ratio-1.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.05
Revenue Forecast (FY)N/A
Spago Nanomedical AB Business Overview & Revenue Model
Company Description
Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a g...
How the Company Makes Money
null...
Spago Nanomedical AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
55
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 107.00K | 437.00K | 1.91M | 1.20M | 1.05M | 660.00K |
| Gross Profit | -17.19M | -19.38M | -12.36M | -23.28M | -15.60M | -16.78M |
| EBITDA | -20.80M | -26.39M | -33.40M | -42.22M | -38.73M | -38.69M |
| Net Income | -19.65M | -26.55M | -32.51M | -42.22M | -39.31M | -39.08M |
Balance Sheet | ||||||
| Total Assets | 30.34M | 36.68M | 39.58M | 52.98M | 205.95M | 191.62M |
| Cash, Cash Equivalents and Short-Term Investments | 25.92M | 29.67M | 32.47M | 45.22M | 62.10M | 52.46M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 6.14M | 5.94M | 6.35M | 11.67M | 8.80M | 6.81M |
| Stockholders Equity | 24.20M | 30.75M | 33.23M | 41.32M | 197.16M | 184.81M |
Cash Flow | ||||||
| Free Cash Flow | -17.75M | -28.53M | -34.90M | -45.06M | -42.02M | -40.20M |
| Operating Cash Flow | -17.75M | -28.30M | -34.67M | -44.91M | -38.19M | -35.57M |
| Investing Cash Flow | -79.00K | 633.00K | -230.00K | -506.00K | -3.83M | -4.63M |
| Financing Cash Flow | 24.43M | 24.87M | 22.15M | 28.53M | 51.66M | 64.21M |
Spago Nanomedical AB Technical Analysis
Negative
0.10
Price Trends
0.12
Negative
0.12
Negative
0.13
Negative
Market Momentum
>-0.01
Negative
46.41
Neutral
61.90
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SPAGO, the sentiment is Negative. The current price of 0.1 is below the 20-day moving average (MA) of 0.11, below the 50-day MA of 0.12, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.41 is Neutral, neither overbought nor oversold. The STOCH value of 61.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SPAGO.
Spago Nanomedical AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | kr188.06M | 2.06 | -294.38% | ― | 57.22% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | kr49.14M | -2.58 | -457.91% | ― | ― | -28.21% | |
49 Neutral | kr117.41M | -2.76 | -52.45% | ― | 7.80% | 42.81% | |
45 Neutral | kr95.01M | -3.00 | -106.95% | ― | -93.63% | 29.24% | |
42 Neutral | kr17.73M | -0.43 | -120.13% | ― | ― | 24.27% |
* Healthcare Sector Average
SE:SPAGO
Spago Nanomedical AB
0.12
-0.07
-38.42%
SE:BIOSGN
Biosergen AB
7.55
-47.25
-86.22%
SE:NICA
Nanologica AB
0.57
-0.58
-50.43%
SE:MODTX
Modus Therapeutics Holding AB
0.40
-0.10
-19.84%
SE:NXTCL
NextCell Pharma AB
1.05
0.06
5.72%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.